# Signal Amplification in the HPT Axis—Evidence for Its Existence, Location, Significance, and Molecular Mechanisms

**Authors:** Li Jing, Sarahna A. Moyd, Qiang Zhang

PMC · DOI: 10.1111/apha.70202 · 2026-03-20

## TL;DR

This paper explores how the HPT axis maintains stable thyroid hormone levels through signal amplification in the brain, offering insights into its mechanisms and implications for thyroid health.

## Contribution

The paper introduces the concept of signal amplification in the brain as a key mechanism for robust thyroid hormone homeostasis.

## Key findings

- Signal amplification occurs in the brain, not the thyroid, to maintain stable thyroid hormone levels.
- Multiple signaling pathways in the hypothalamus and pituitary amplify T3 signals for effective feedback control.
- This mechanism provides evolutionary advantages by minimizing disruptions to thyroid hormone levels.

## Abstract

Thyroid hormones (THs) are under negative feedback regulation via the hypothalamic–pituitary‐thyroid (HPT) axis. How this axis operates to keep the circulating THs within a narrow physiological range is not well understood quantitatively. Led by the design principle of robust homeostatic feedback control, here we review and synthesize the literature under a unifying theme of signal amplification in the HPT axis, providing evidence for its existence, location, functional significance, and potential molecular mechanisms. Drawing on human studies of the circulating TSH‐T4 relationship, we assert that a signal amplifier exists in the brain, where the TH feedback signal is amplified to inhibit TRH and TSH. With mathematical models we illustrate that placing the signal amplifier of the HPT feedback loop in the brain, not in the thyroid, provides an evolutionary advantage, which minimizes the disruption of operating TH levels by possible perturbations. We review the molecular neuroendocrine literature to reveal how signal amplification (ultrasensitivity) is likely achieved mechanically in the hypothalamus and anterior pituitary. We identify multiple signaling pathways in the TRH neurons, β2‐tanycytes, and thyrotropes that mediate the feedback action of THs, including transcriptional and posttranslational regulations of the synthesis, maturation, degradation, and release of TRH and TSH. Collectively, these multistep regulations amplify T3 signal, providing a high feedback loop gain for robust TH homeostatic control. The nature's design principle revealed here enhances our cross‐scale understanding of the systems biology of the HPT axis as a dynamical control system, which can promote precision thyroid medicine and risk assessment of thyroid‐disrupting chemicals.

## Full-text entities

- **Genes:** Thrb (thyroid hormone receptor beta) [NCBI Gene 24831] {aka C-erba-beta, ERBA2, Nr1a2, RATT3REC, T3rec, TRbeta}, Pde10a (phosphodiesterase 10A) [NCBI Gene 63885] {aka Pde10a3}, CGA (glycoprotein hormones, alpha polypeptide) [NCBI Gene 1081] {aka CG-ALPHA, FSHA, GPA1, GPHA1, GPHa, HCG}, Trib1 (tribbles pseudokinase 1) [NCBI Gene 211770] {aka A530090O15Rik, TRB-1, Trb1}, Tshb (thyroid stimulating hormone subunit beta) [NCBI Gene 25653], Chga (chromogranin A) [NCBI Gene 24258], LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, Gpbar1 (G protein-coupled bile acid receptor 1) [NCBI Gene 338443] {aka M-BAR, Tgr5}, Trh (thyrotropin releasing hormone) [NCBI Gene 25569] {aka Pro-TRH, THR, TRH01, Trf}, Hspg2 (perlecan (heparan sulfate proteoglycan 2)) [NCBI Gene 15530] {aka HSPG, Pcn, Plc, per}, Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, Pth (parathyroid hormone) [NCBI Gene 24694] {aka PTH-(1-84), Pth1, Pthr1}, Tas2r134 (taste receptor, type 2, member 134) [NCBI Gene 295589] {aka GPCR, T2R134, T2R23, T2R34}, Dio1 (iodothyronine deiodinase 1) [NCBI Gene 25430] {aka 5DI, ITDI1, TXDI1}, Prkcg (protein kinase C, gamma) [NCBI Gene 24681] {aka PKC, PKCI, Prkc, Prkcc, RATPKCI}, Trh (thyrotropin releasing hormone) [NCBI Gene 22044] {aka Pro-TRH, Trf}, Slc16a10 (solute carrier family 16 (monocarboxylic acid transporters), member 10) [NCBI Gene 72472] {aka 2610103N14Rik, 9830169E08, Mct10, PRO0813, TAT1}, Ugt1a2 (UDP glucuronosyltransferase 1 family, polypeptide A2) [NCBI Gene 396527] {aka UDPGT 1-2, Udpgt, Ugt1}, TSHB (thyroid stimulating hormone subunit beta) [NCBI Gene 7252] {aka TSH-B, TSH-BETA}, Cnr1 (cannabinoid receptor 1) [NCBI Gene 12801] {aka CB-R, CB1, CB1A, CB1B, CB1R}, Slc16a10 (solute carrier family 16 member 10) [NCBI Gene 170566] {aka Tat1}, Prl3d1l1 (prolactin family 3, subfamily D, member 1 like 1) [NCBI Gene 53950] {aka Csh1, Pl-I, Pl-Im, Pl1, Prl3d1, Rhco1}, Capzb (capping actin protein of muscle Z-line subunit beta) [NCBI Gene 298584], Pde8b (phosphodiesterase 8B) [NCBI Gene 309962] {aka RNPDE8B}, Ttr (transthyretin) [NCBI Gene 24856] {aka Lr1, TT, Tbpa}, Lhx2 (LIM homeobox 2) [NCBI Gene 296706] {aka LH2A, Lh-2}, Thra (thyroid hormone receptor alpha) [NCBI Gene 81812] {aka ERBA1, Thra1, c-erbA-1}, Th (tyrosine hydroxylase) [NCBI Gene 25085] {aka The}, DIO2 (iodothyronine deiodinase 2) [NCBI Gene 1734] {aka 5DII, D2, DIOII, SELENOY, SelY, TXDI2}, Cga (glycoprotein hormones, alpha subunit) [NCBI Gene 12640] {aka CG-alpha, FSHA, GPHA1, GPHalpha, HCG, LHA}, Tshr (thyroid stimulating hormone receptor) [NCBI Gene 25360] {aka TSHRA}, Igf1 (insulin-like growth factor 1) [NCBI Gene 24482] {aka IGF}, Pabpc1 (poly(A) binding protein, cytoplasmic 1) [NCBI Gene 171350] {aka PABP 1, Pabp, Pabp1}, TSHR (thyroid stimulating hormone receptor) [NCBI Gene 7253] {aka CHNG1, LGR3, hTSHR-I}, Pcsk1 (proprotein convertase subtilisin/kexin type 1) [NCBI Gene 25204] {aka BDP, PC1, PC3}, Tshb (thyroid stimulating hormone, beta subunit) [NCBI Gene 22094], Slc16a2 (solute carrier family 16 member 2) [NCBI Gene 259248], Tpo (thyroid peroxidase) [NCBI Gene 54314], Nr4a1 (nuclear receptor subfamily 4, group A, member 1) [NCBI Gene 79240] {aka HMR, Ngfi-b, Nur77}, Gata2 (GATA binding protein 2) [NCBI Gene 25159], Hdac3 (histone deacetylase 3) [NCBI Gene 84578], Grk2 (G protein-coupled receptor kinase 2) [NCBI Gene 25238] {aka Adrbk1, BARK1, GRK-2}, Agrp (agouti related neuropeptide) [NCBI Gene 25582], Pcsk2 (proprotein convertase subtilisin/kexin type 2) [NCBI Gene 25121], Prl (prolactin) [NCBI Gene 24683] {aka Gha1, PRLB, PRLSD1, Prl1a1, Prol, RATPRLSD1}, Hsp90b1 (heat shock protein 90 beta family member 1) [NCBI Gene 362862] {aka Grp94, Tra1}, Dagla (diacylglycerol lipase, alpha) [NCBI Gene 269060] {aka Nsddr}, Pam (peptidylglycine alpha-amidating monooxygenase) [NCBI Gene 25508] {aka PHM}, Ggh (gamma-glutamyl hydrolase) [NCBI Gene 25455], Insr (insulin receptor) [NCBI Gene 24954], Tas2r103 (taste receptor, type 2, member 103) [NCBI Gene 667992] {aka EG667992, T2R3, TRB2, Tas2r10, Tas2r3, mGR03}, Creb1 (cAMP responsive element binding protein 1) [NCBI Gene 81646] {aka Creb}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 83785] {aka VEGF-A, VEGF111, VEGF164, VPF, Vegf}, Tshr (thyroid stimulating hormone receptor) [NCBI Gene 22095] {aka hypothroid, hyt, pet}, Nfia (nuclear factor I/A) [NCBI Gene 25492], Cpe (carboxypeptidase E) [NCBI Gene 25669] {aka CARBE, Cph}, Rxrb (retinoid X receptor beta) [NCBI Gene 361801] {aka RXR-beta}, Trhde (thyrotropin-releasing hormone degrading enzyme) [NCBI Gene 366894] {aka PAP-II}, Th (tyrosine hydroxylase) [NCBI Gene 21823], DIO1 (iodothyronine deiodinase 1) [NCBI Gene 1733] {aka 5DI, THMA2, TXDI1}
- **Diseases:** iodine deficiency (MESH:D003409), hyperthyroid (MESH:D006980), growth retardation (MESH:D006130), AP (MESH:D010900), non-HPT (MESH:D007029), genetic disorders (MESH:D030342), thyroid EDCs (MESH:D004700), cancers (MESH:D009369), thyrotoxicosis (MESH:C566386), Hypothyroidism (MESH:D007037), thyroid conditions (MESH:D013959), pituitary thyrotropic tumor (MESH:D010911)
- **Chemicals:** AP (MESH:D010908), glycan (MESH:D011134), N (MESH:D009584), Pro (MESH:D011392), glucose (MESH:D005947), norepinephrine (MESH:D009638), 12-O-tetradecanoylphorbol-13-acetate (MESH:D013755), mannose (MESH:D008358), zinc (MESH:D015032), glucosamine (MESH:D005944), Gly (MESH:D005998), carbohydrate (MESH:D002241), IP3 (MESH:D015544), Flux (MESH:C040639), oligosaccharides (MESH:D009844), Asn (MESH:D001216), PTU (MESH:D011441), GlcNAc (MESH:D000117), follicle-stimulating hormone (MESH:D005640), Gln (MESH:D005973), methimazole (MESH:D008713), DAG (MESH:D004075), glutamate (MESH:D018698), sialic acids (MESH:D012794), salt (MESH:D012492), endocannabinoid (MESH:D063388), perchlorate (MESH:C494474), T3 (MESH:D014284), phorbol esters (MESH:D010703), L-T4 (MESH:D013974), PIP2 (MESH:D019269), 2-arachinodonoylglycerol (-), iodine (MESH:D007455), cortisol (MESH:D006854), sobetirome (MESH:C413355), EMD 21388 (MESH:C057452), calcium (MESH:D002118), luteinizing hormone (MESH:D007986)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Cercopithecidae (monkey, family) [taxon 9527], Rodentia (rodent, order) [taxon 9989], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** E460K, A317T
- **Cell lines:** TtT97 — Mus musculus (Mouse), Mouse pituitary gland neoplasms, Cancer cell line (CVCL_U804), GH4C1 — Rattus norvegicus (Rat), Rat pituitary gland neoplasm, Cancer cell line (CVCL_0276), 3C — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_1098), line — Mus musculus (Mouse), Adenoma of the mouse pulmonary system, Cancer cell line (CVCL_5V03), alpha-23 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_U992), CD-1 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_5731), GH3 — Rattus norvegicus (Rat), Rat pituitary gland neoplasm, Cancer cell line (CVCL_0273), MGH101A — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_W785), TtT — Mesocricetus auratus (Golden hamster), Hamster pituitary carcinoma, Cancer cell line (CVCL_5M18), TalphaT1 — Mus musculus (Mouse), Transformed cell line (CVCL_U355), CV-1 — Chlorocebus aethiops (Green monkey), Finite cell line (CVCL_0229)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13004654/full.md

---
Source: https://tomesphere.com/paper/PMC13004654